CN111971090B - 双特异性egfr/cd16抗原结合蛋白 - Google Patents

双特异性egfr/cd16抗原结合蛋白 Download PDF

Info

Publication number
CN111971090B
CN111971090B CN201980018525.9A CN201980018525A CN111971090B CN 111971090 B CN111971090 B CN 111971090B CN 201980018525 A CN201980018525 A CN 201980018525A CN 111971090 B CN111971090 B CN 111971090B
Authority
CN
China
Prior art keywords
ser
egfr
gly
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980018525.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111971090A (zh
Inventor
迈克尔·克卢格
迈克尔·特萨
伊维卡·法斯克
克里斯蒂娜·埃尔万格尔
乌维·罗伊施
迈克尔·达姆拉特
埃里希·拉伊科维奇
马丁·特雷德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of CN111971090A publication Critical patent/CN111971090A/zh
Application granted granted Critical
Publication of CN111971090B publication Critical patent/CN111971090B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980018525.9A 2018-03-14 2019-03-14 双特异性egfr/cd16抗原结合蛋白 Active CN111971090B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161871 2018-03-14
EP18161871.1 2018-03-14
PCT/EP2019/056516 WO2019175368A1 (en) 2018-03-14 2019-03-14 Bispecific egfr/cd16 antigen-binding protein

Publications (2)

Publication Number Publication Date
CN111971090A CN111971090A (zh) 2020-11-20
CN111971090B true CN111971090B (zh) 2024-02-23

Family

ID=61683598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018525.9A Active CN111971090B (zh) 2018-03-14 2019-03-14 双特异性egfr/cd16抗原结合蛋白

Country Status (13)

Country Link
US (2) US11510972B2 (https=)
EP (1) EP3765157A1 (https=)
JP (1) JP7288913B2 (https=)
KR (1) KR102924742B1 (https=)
CN (1) CN111971090B (https=)
AU (1) AU2019235433B2 (https=)
BR (1) BR112020018492A2 (https=)
CA (1) CA3090464A1 (https=)
IL (1) IL276903B2 (https=)
MX (1) MX2020009445A (https=)
SG (1) SG11202007664WA (https=)
WO (1) WO2019175368A1 (https=)
ZA (1) ZA202006247B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276903B2 (en) * 2018-03-14 2025-12-01 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
KR20220119467A (ko) 2019-12-27 2022-08-29 아피메트 게엠베하 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116143942A (zh) * 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
JP2024543828A (ja) * 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
AU2022382368A1 (en) * 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
WO2024186092A1 (ko) * 2023-03-06 2024-09-12 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2024213097A1 (zh) * 2023-04-14 2024-10-17 山东先声生物制药有限公司 一种靶向人cd16和肿瘤抗原的多特异性抗体
WO2025167357A1 (zh) * 2024-02-06 2025-08-14 启愈生物技术(上海)有限公司 Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用
WO2026017120A1 (zh) * 2024-07-18 2026-01-22 信达生物制药(苏州)有限公司 抗cdh17/egfr/cd16a三特异性抗体及其用途
CN118994409B (zh) * 2024-07-30 2025-07-22 郑州市乘黄生物医药科技有限公司 结合CD16A和Trop2的双特异性抗体-NK细胞偶联物及其用途
CN118791616A (zh) * 2024-09-14 2024-10-18 苏州为度生物技术有限公司天津分公司 一种抗人cd16工程抗体及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105367660A (zh) * 2015-12-22 2016-03-02 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
CN105555804A (zh) * 2013-08-07 2016-05-04 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
CN106661108A (zh) * 2014-04-13 2017-05-10 阿菲姆德股份有限公司 三功能抗原结合分子

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8289183B1 (en) 2008-04-25 2012-10-16 Texas Instruments Incorporated System and method for solar panel array analysis
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN105153307A (zh) * 2010-05-04 2015-12-16 梅里麦克制药股份有限公司 抗表皮生长因子受体(egfr)的抗体及其用途
LT2794658T (lt) * 2011-12-19 2017-05-10 Synimmune Gmbh Bispecifinė antikūno molekulė
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
AU2014227638A1 (en) 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
TWI731535B (zh) * 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
ES2754557T3 (es) * 2015-05-04 2020-04-20 Affimed Gmbh Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
IL276903B2 (en) * 2018-03-14 2025-12-01 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105555804A (zh) * 2013-08-07 2016-05-04 阿菲姆德股份有限公司 对EGFRvIII有特异性的抗体结合位点
CN106661108A (zh) * 2014-04-13 2017-05-10 阿菲姆德股份有限公司 三功能抗原结合分子
CN105367660A (zh) * 2015-12-22 2016-03-02 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体

Also Published As

Publication number Publication date
BR112020018492A2 (pt) 2020-12-29
JP7288913B2 (ja) 2023-06-08
KR20200132919A (ko) 2020-11-25
IL276903A (en) 2020-10-29
CN111971090A (zh) 2020-11-20
KR102924742B1 (ko) 2026-02-10
IL276903B2 (en) 2025-12-01
ZA202006247B (en) 2021-09-29
MX2020009445A (es) 2020-10-08
US20230190900A1 (en) 2023-06-22
AU2019235433A1 (en) 2020-08-27
WO2019175368A1 (en) 2019-09-19
US11510972B2 (en) 2022-11-29
CA3090464A1 (en) 2019-09-19
US12076384B2 (en) 2024-09-03
US20200405833A1 (en) 2020-12-31
RU2020131234A (ru) 2022-03-22
AU2019235433B2 (en) 2025-11-20
IL276903B1 (en) 2025-08-01
JP2021515798A (ja) 2021-06-24
EP3765157A1 (en) 2021-01-20
SG11202007664WA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CN111971090B (zh) 双特异性egfr/cd16抗原结合蛋白
US11639386B2 (en) Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
US11274142B2 (en) Fusion protein containing TGF-β receptor and medicinal uses thereof
CN109715663B (zh) 结合生长抑素受体2的异源二聚抗体
CN109641049B (zh) Cd3结合抗体
CN109843325B (zh) Cd3结合抗体
CN110066338B (zh) 作为T细胞衔接器的双特异性IgG抗体
WO2023051727A1 (zh) 结合cd3的抗体及其用途
JP2020533362A (ja) エクト酵素に結合する重鎖抗体
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
JP2019529368A (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
JP2021505637A (ja) 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
RU2792240C2 (ru) Биспецифический антигенсвязывающий белок egfr/cd16
JP2022520817A (ja) Ｆｃｍｒ結合分子およびそれらの使用
WO2026046399A1 (en) Anti-dll3 antibodies and use thereof
WO2022262749A1 (zh) 靶向pd1和/或ox40的特异性结合蛋白
WO2022037582A1 (zh) 抗cd3和抗cldn-18.2双特异性抗体及其用途
JP2022525261A (ja) ビスタ結合抗体およびその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant